Cargando…

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

PURPOSE: Risk of infection increases with severity and duration of chemotherapy-induced neutropenia (CIN). Pegfilgrastim is approved for use on the day after chemotherapy to reduce incidence of infection, as manifested by febrile neutropenia (FN), in patients receiving myelosuppressive chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yanli, Klippel, Zandra, Shih, Xiaolong, Wang, Hong, Reiner, Maureen, Page, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819939/ https://www.ncbi.nlm.nih.gov/pubmed/26886017 http://dx.doi.org/10.1007/s00280-016-2970-5

Ejemplares similares

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
por: Weycker, Derek, et al.
Publicado: (2015)

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia
por: Li, Yanli, et al.
Publicado: (2018)

Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
por: Lee, Ji Won, et al.
Publicado: (2022)

Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy
por: Fournier, Q., et al.
Publicado: (2017)

Immature Reticulocyte Fraction and Absolute Neutrophil Count as Predictor of Hemopoietic Recovery in Patients with Acute Lymphoblastic Leukemia on Remission Induction Chemotherapy
por: Rauf, Shan E., et al.
Publicado: (2016)

Constancy of the Day-To-Day Leucocyte Blood Count
por: Harvey, W. F., et al.
Publicado: (1934)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer
por: Chu-Yuan, Hong, et al.
Publicado: (2013)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
por: Scholz, Markus, et al.
Publicado: (2009)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Absolute neutrophil count nadir in healthy pediatric patients with the Duffy-null phenotype
por: Merz, Lauren E., et al.
Publicado: (2023)

Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial
por: Park, Kwonoh, et al.
Publicado: (2023)

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
por: Kubo, Kohmei, et al.
Publicado: (2016)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
por: Kahan, Zsuzsanna, et al.
Publicado: (2019)

Absolute lymphocyte and neutrophil counts in neonatal ischemic brain injury
por: Povroznik, Jessica M, et al.
Publicado: (2018)

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types
por: Morisaki, Tamami, et al.
Publicado: (2021)

1754 Days to the LHC and counting!
Publicado: (2001)

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
por: Affronti, Mary Lou, et al.
Publicado: (2014)

Absolute neutrophil count by Duffy status among healthy Black and African American adults
por: Merz, Lauren E., et al.
Publicado: (2022)

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study
por: Kowalyszyn, Ruben D., et al.
Publicado: (2022)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma
por: Puar, Neha, et al.
Publicado: (2019)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine
por: Gee, Siobhan, et al.
Publicado: (2020)

Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
por: Ramli, Fitri Fareez, et al.
Publicado: (2021)

Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy
por: Borniger, Jeremy C., et al.
Publicado: (2017)

One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis
por: Watanabe, Daichi, et al.
Publicado: (2022)

Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
por: Junlén, Henna-Riikka, et al.
Publicado: (2020)

Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients
por: Bi, Yazhen, et al.
Publicado: (2022)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020)

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy
por: Ito, Takanori, et al.
Publicado: (2023)

Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib
por: Chen, Rong, et al.
Publicado: (2021)

Pileup of Insufficient Sleep and Day-to-Day Trajectories of Affective and Physical Well-Being
por: Lee, Soomi
Publicado: (2021)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
por: Desai, Kalpna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4uvkb695t7cohg2bp53uonshib